| Date Filed | Type | Description |
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 07/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
8-K
| Appointed a new director |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 03/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/24/2023 |
SC 13D/A
| NEUROCRINE BIOSCIENCES INC reports a 19.9% stake in VOYAGER THERAPEUTICS, INC. |
| 02/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| Third Rock Ventures III, L.P. reports a 14.2% stake in Voyager Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 8.8% stake in Voyager Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 5.1% stake in Voyager Therapeutics Inc. |
| 01/13/2023 |
SC 13G/A
| EcoR1 Capital, LLC reports a 10% stake in Voyager Therapeutics, Inc. |
| 01/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Secur... |
| 12/14/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/08/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 10/04/2022 |
8-K
| Other Events Interactive Data |
| 09/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"EMPLOYMENT AGREEMENT This Employment Agreement is made as of September 7, 2022 by and between Voyager Therapeutics, Inc. and Peter Pfreundschuh . 1.             Employment . The Company and the Executive desire that the Executive be employed as the Company’ s Chief Financial Officer. The employment relationship between the Company and the Executive shall be governed by this Agreement commencing as of the Effective Date and continuing in effect until terminated by either party in accordance with this Agreement. The Executive’ s first day of employment shall be September 19, 2022 . At all times, the Executive’ s employment with the Company will be “at-will,” meaning that the Executive’ s employment may be terminated by t...",
"SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT   This Second Amended and Restated Employment Agreement is made as of September 7, 2022 by and between Voyager Therapeutics, Inc. and Todd Carter, Ph.D. .   WHEREAS, the Company and the Executive are parties to a certain Amended and Restated Employment Agreement dated March 14, 2022 ; and   WHEREAS, the Company and the Executive desire that this Agreement shall amend, supersede, and control over the Original Agreement as of the Effective Date.   NOW, THEREFORE, in consideration of the covenants and obligations set forth below, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:   1.    R..." |
|
|